
A phase 3 trial investigated dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) for oropharyngeal and hypopharyngeal cancer. Participants received DO-IMRT or standard IMRT, with DO-IMRT aiming to reduce radiation dose to dysphagia-related structures. DO-IMRT group reported significantly improved swallowing function (MDADI composite score) at 12 months (77.7 vs 70.6, p=0.037). Serious adverse events were reported but not linked to treatment. DO-IMRT shows promise in enhancing patient-reported swallowing function and could become the new standard of care for pharyngeal cancer radiotherapy.
Like
Save
Share